Catalyst Wire Dossier Catalyst Wire Dossier

CRISPR PD-1-edited tumor-infiltrating lymphocytes

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CRISPR PD-1-edited tumor-infiltrating lymphocytes, covering 2025-01-20 to 2025-01-20. Get the full timeline:

Most recent: Clinical Trial Update: T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma [Phase 1]

See pricing